Skip to main content
Equibles
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track KYMR — free

Use KYMR with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYMR.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$109.44 -0.68 (-0.62%)
Russell 2000 member Rebalance outlook locked
Market Cap
$9.31B
Shares
83.15M
Volume · Oct 1 1.05M Avg daily vol (3M) 687.63K

Kymera Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Kymera Therapeutics, Inc. (KYMR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼53% $9.55M −$43.00M '22 Q3 22-11-03 ▲5.7% $16.14M −$34.87M '22 Q4 23-01-10 ▼1.6% $9.47M −$40.93M '23 Q1 23-05-04 ▲43.4% $16.51M −$38.80M '23 Q2 23-08-03 ▼50.5% $4.73M −$52.87M '23 Q3 23-11-02 ▲196.7% $47.88M −$14.37M '23 Q4 24-02-22 ▲8.7% $10.29M −$48.56M '24 Q1 24-05-02 ▲55.3% $25.65M −$42.06M '24 Q2 24-08-07 ▼20.9% $3.74M −$62.49M '24 Q3 24-10-31 ▼84.6% $7.39M −$70.75M '24 Q4 25-02-27 ▲114.8% $22.10M −$65.58M '25 Q1 25-05-09 ▼55.3% $11.48M −$76.61M '25 Q2 25-08-11 ▼26.1% $2.76M −$82.17M '25 Q3 25-11-04 ▼61.2% $2.87M −$86.98M '25 Q4 26-02-26 ▲55.5% $34.37M −$69.23M '26 Q1 26-04-30 LATEST ▲466.4% $65.00M −$61.21M '26 Q2 26-08-05
Conference
Investor event
2026-09-15
Kymera Therapeutics, Inc. (KYMR) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Kymera Therapeutics, Inc. (KYMR) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Kymera Therapeutics, Inc. (KYMR) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Confident tone KT-621 Asthma and other type 2 indications Financial strength and runway Pediatric and label expansion strategy
Revenue
$65.00M
▲ 466.4% YoY
Diluted EPS
$-0.62
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Kymera Therapeutics, Inc. (KYMR) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call
Revenue
$34.37M
▲ 55.5% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-12
Kymera Therapeutics, Inc. (KYMR) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Confident tone KT-579 IRF5 Degrader for Lupus KT-621 STAT6 Degrader in Atopic Dermatitis and Asthma Pipeline Expansion and New Development Candidate
Revenue
$2.87M*
▼ 61.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
Confident tone KT-621 STAT6 program BroADen Phase Ib data readout Asthma and pediatric opportunity
Revenue
$2.76M
▼ 26.1% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
Confident tone KT-621 STAT6 program Phase IIb dose selection and trial planning Biomarker and clinical endpoint expectations
Revenue
$11.48M
▼ 55.3% YoY
Diluted EPS
$-0.95
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
Confident tone IRAF5 program introduction Immunology opportunity and market Clinical execution and milestones
Revenue
$22.10M
▲ 114.8% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Confident tone STAT6 / KT-621 program New immunology target / pipeline expansion Clinical readout timing risks
Revenue
$7.39M*
▼ 84.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
Confident tone KT-621 STAT6 degrader Phase 1 TYK2 program progression Partnership considerations for STAT6
Revenue
$3.74M
▼ 20.9% YoY
Diluted EPS
$-0.82
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
Confident tone KT-621 / STAT6 program KT-474 / IRAK4 program Pipeline and platform
Revenue
$25.65M
▲ 55.3% YoY
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
Confident tone IRAK4 / KT-474 program STAT6 degrader KT-621 TYK2 degrader KT-294
Revenue
$10.29M
▲ 8.7% YoY
Diluted EPS
$-0.69
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Kymera Therapeutics, Inc. (KYMR) Q4 2023 Earnings Call Transcript
Confident tone STAT6 degrader (KT-621) IRAK4 / KT-474 program with Sanofi TYK2 degrader (KT-294)
Revenue
$47.88M*
▲ 196.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Revenue
$4.73M
▼ 50.5% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kymera Therapeutics, Inc. (KYMR) Q2 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 43.4% YoY
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Kymera Therapeutics, Inc. (KYMR) Q1 2023 Earnings Call Transcript
Revenue
$9.47M
▼ 1.6% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Call Transcript
Revenue
$16.14M*
▲ 5.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kymera Therapeutics, Inc. (KYMR) Q3 2022 Earnings Call Transcript
Revenue
$9.55M
▼ 53% YoY
Diluted EPS
$-0.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Kymera Therapeutics, Inc. (KYMR) Q2 2022 Earnings Call Transcript
Revenue
$11.51M
▼ 37.8% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kymera Therapeutics, Inc. (KYMR) Q1 2022 Earnings Call Transcript
Revenue
$9.62M
▼ 48.6% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–23 of 23 webcasts
Key facts CIK 1815442 CUSIP 501575104 13F (30d) 7 filings 7 filers Visit website Investor relations